These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 9867542)

  • 1. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR; Martin MB
    N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation with oral deferiprone in patients with thalassemia.
    Stella M; Pinzello G; Maggio A
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867539
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron chelation with oral deferiprone in patients with thalassemia.
    Callea F
    N Engl J Med; 1998 Dec; 339(23):1710-1; author reply 1713-4. PubMed ID: 9867537
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron chelation with oral deferiprone in patients with thalassemia.
    Tricta F; Spino M
    N Engl J Med; 1998 Dec; 339(23):1710; author reply 1713-4. PubMed ID: 9867536
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron chelation with oral deferiprone in patients with thalassemia.
    Nathan DG; Weatherall DJ
    N Engl J Med; 1998 Dec; 339(23):1711-2; author reply 1713-4. PubMed ID: 9867538
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron chelation with oral deferiprone in patients with thalassemia.
    Wonke B; Telfer P; Hoffbrand AV
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867540
    [No Abstract]   [Full Text] [Related]  

  • 11. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term deferiprone chelation therapy.
    Hoffbrand VA; Wonke B
    Adv Exp Med Biol; 2002; 509():127-39. PubMed ID: 12572992
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral iron chelation therapy for thalassaemia: an uncertain scene.
    Pippard MJ; Weatherall DJ
    Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.
    Piga A; Gaglioti C; Fogliacco E; Tricta F
    Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelators for thalassaemia.
    Hershko C; Konijn AM; Link G
    Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
    [No Abstract]   [Full Text] [Related]  

  • 20. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
    Martín M; Estornell J; Orero M; Pérez JL; Ridocci F; Martínez V
    Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.